
Savara Inc. Publishes Promising Long-Term Outcomes for aPAP Treatment
LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has announced the publication of a manuscript detailing long-term outcomes for molgramostim inhalation solution in patients with autoimmune pulmonary alveolar proteinosis (aPAP). The study, …
Savara Inc. Publishes Promising Long-Term Outcomes for aPAP Treatment Read More